Ligia Carolina Facin: Investigating a Novel Therapeutic Strategy for ATTR-CM
Ligia Carolina Facin, Fellowship in Cardiac Amyloidosis at Ensino InCor, Cardio-Oncology Resident at Heart Institute, University of São Paulo (FMUSP), shared a post on LinkedIn:
“It was a great privilege to participate in the CLEOPATTRA Investigators’ Meeting, an international clinical trial investigating a novel therapeutic strategy for transthyretin amyloid cardiomyopathy (ATTR-CM).
Over the past few years, we have witnessed remarkable advances in the treatment of ATTR-CM.
Now, a new frontier is being explored: therapies aimed at removing amyloid deposits already present in cardiac tissue, with the potential to further transform the course of the disease.
Being part of a study investigating this innovative therapeutic approach is a unique opportunity to contribute to the evidence that may shape the future of cardiac amyloidosis treatment.
Science, international collaboration, and clinical research opening new perspectives for our patients.”
Stay updated with Hemostasis Today.
-
Oct 5, 2026, 15:31Irma Bagdoniene: Multidisciplinary Management of High-Risk Familial Hypercholesterolaemia and CAD
-
Oct 5, 2026, 15:00Serena Williams and Pulmonary Embolism: From Personal Crisis to Lessons in Venous Thromboembolism
-
Oct 5, 2026, 14:55Marco Moscarelli: 3D Reconstruction Enhances Volumetric Assessment of Post-TAVI Thrombosis
-
Oct 5, 2026, 13:24Abdul Muqtadir Abbasi: Diagnostic Pearls for Evaluating Isolated Thrombocytopenia in Residents
-
Oct 5, 2026, 13:16Katerina Pavenski: Rethinking What ‘Normal’ Means for Iron Deficiency
-
Oct 5, 2026, 13:09Rick Matthews: Balancing Established VTE Partnerships with Innovative Interventional Technologies
-
Oct 5, 2026, 13:01Nawsherwan Mohammad: Recognizing TTP Before the ADAMTS13 Result Arrives
-
Oct 5, 2026, 12:51Bruno Pougault: The Hidden Challenges Behind Anti Xa Testing
-
Oct 5, 2026, 12:41Syed Huzaifa Khan: Rethinking CTRP12 as a Biomarker for In Stent Restenosis